How much cash does Niagen Bioscience, Inc. Common Stock generate?

Niagen Bioscience, Inc. Common Stock (NAGE) generated $4.4M in operating cash flow over the trailing twelve months.

Where does Niagen Bioscience, Inc. Common Stock's cash flow data come from?

Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Niagen Bioscience, Inc. Common Stock NAGE Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	$18.64M+32.1%	$17.38M+103%	$20.43M+1,390%	$17.73M+1,309%	$14.11M+487%
Depreciation and amortization	$570K-11.4%	$612K-7.7%	$624K-9.4%	$631K-16.8%	$643K-21.6%
Stock-based compensation	$6.71M+79.0%	$6.07M+65.9%	$5.07M+28.7%	$4.05M-6.3%	$3.75M-16.0%
Gain (loss) on sale of assets	——	——	——	$16K+967%	$19K+407%
Provision for credit losses	——	——	——	——	-$2.61M-503%
Change in inventories	$13.22M+1,109%	$11.64M+318%	$8.25M—	$2.9M—	-$1.31M—
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	$507K-65.4%	$1.84M+52.7%	$1.99M+399%	$1.64M+203%	$1.47M—
Change in other assets	-$932K-811%	-$1.12M-2,591%	-$18K—	$78K—	$131K—
Other working capital changes	-$58K+19.4%	-$59K+26.3%	-$59K+23.4%	-$65K+12.2%	-$72K+4.0%
Change in deferred revenue	——	——	——	-$637K-28.7%	-$767K-27.2%
Amortization of intangible assets	$311K+107%	$173K+14.6%	$151K—	$151K—	$150K—
Change in operating lease liabilities	-$939K-14.8%	-$949K-54.3%	-$955K-118%	-$947K-163%	-$818K-106%
Change in receivables	$6.21M—	$756K—	——	——	——
Net cash from operating activities	$4.43M-77.8%	$13.5M+9.1%	$21.41M+382%	$21.21M+1,483%	$19.96M+332%
Proceeds from sale of businesses	——	——	——	——	——
Net cash from investing activities	$4.99M+3,820%	-$292K-104%	-$260K-174%	-$257K-157%	-$134K-44.1%
Repurchases of common stock	——	——	——	——	$0—
Proceeds from issuance of common stock	$4.24M-50.4%	$7.25M+33.4%	$10.81M+559%	$11.7M+1,857%	$8.55M—
Payments for finance leases	$9K-18.2%	$12K+9.1%	$12K+20.0%	$12K+33.3%	$11K-35.3%
Payment of debt issuance costs	$61K—	$67K—	$53K—	——	——
Net cash from financing activities	$1.6M-81.1%	$7M+30.3%	$10.74M+595%	$11.64M+2,213%	$8.49M+8,341%
Net increase (decrease) in cash	$10.93M-61.0%	$20.13M+16.1%	$31.89M+467%	$32.59M+2,103%	$28.05M+534%
Amortization of capitalized software and acquired intangible assets	$311K+107%	$173K+14.6%	$151K-0.7%	$151K-1.3%	$150K-3.2%
Depreciation	$570K-11.4%	$612K-7.7%	$624K-9.4%	$631K-16.8%	$643K-21.6%
Gain on sale of business and assets	——	——	——	——	——
Gain (Loss) On Settlement Of Royalty Obligation	——	$1.98M—	$1.49M—	$991.5K—	$495.75K—
Implementation Costs For Cloud Computing Arrangement	——	$66K-20.5%	$70.25K-9.1%	$74.5K+4.2%	$78.75K+19.8%
Implementation costs for cloud computing arrangement	——	——	——	——	——
Deferred revenue	——	——	——	——	-$24K-130%
Operating lease liabilities	-$939K-14.8%	-$949K-54.3%	-$955K-118%	-$947K-163%	-$818K-106%
Increase (Decrease) in Other Receivables	$6.21M—	$756K—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	-$932K-811%	-$1.12M-2,591%	-$18K—	$78K—	$131K—
Interest accretion on deferred consideration	——	——	——	——	——
Interest accretion on deferred consideration	——	$38K—	$28.5K—	$19K—	$9.5K—
Noncash lease expense	——	——	——	——	——
Noncash lease expense	——	$665K-0.7%	$666.25K-0.8%	$667.5K-0.9%	$668.75K-1.0%
Other Noncash Income (Expense)	-$58K+19.4%	-$59K+26.3%	-$59K+23.4%	-$65K+12.2%	-$72K+4.0%
Accounts Receivable, Credit Loss Expense (Reversal)	——	——	——	——	-$2.61M-503%
Reversal of previously accrued royalties and license maintenance fees	——	$0+100%	-$880.25K+66.7%	-$1.76M0.0%	-$2.64M-200%
Transaction costs from sale of operating segment	——	——	——	——	——
Proceeds from the sale of leasehold improvements and equipment, net	——	$0-100%	$5K-69.2%	$10K-20.0%	$15K+71.4%
Purchases Of Leasehold Improvements And Equipment	——	$292K+79.1%	$259.75K+63.1%	$227.5K+46.3%	$195.25K+28.7%
Purchases of leasehold improvements and equipment	——	——	——	——	——
Finance Lease, Principal Payments	$9K-18.2%	$12K+9.1%	$12K+20.0%	$12K+33.3%	$11K-35.3%
Payments Of Debt Issuance Costs	$61K—	$67K—	$53K—	——	——
Settlement Of Deferred Consideration	——	——	——	——	——
Acquisition of patent intangible asset and deferred consideration liability	——	$5.47M—	$4.11M—	$2.74M—	$1.37M—
Increase Decrease In Contract With Customer Liability	——	——	——	——	——
Increase Decrease In Operating Lease Liability	-$939K-14.8%	-$949K-54.3%	-$955K-118%	-$947K-163%	-$818K-106%
Operating Lease Payments	$804K0.0%	$873K+45.5%	$879K+91.1%	$781K+59.1%	$804K+54.3%
Right-of-use assets and operating lease obligations incurred for entering into lease amendment	——	$1.13M—	$845.25K+658%	$563.5K+153%	$281.75K-15.8%
Right-of-use assets and operating lease obligations incurred for entering into lease amendment	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Niagen Bioscience, Inc. Common Stock.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Niagen Bioscience, Inc. Common Stock generate?: Niagen Bioscience, Inc. Common Stock (NAGE) generated $4.4M in operating cash flow over the trailing twelve months.
Where does Niagen Bioscience, Inc. Common Stock's cash flow data come from?: Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.